Cognition Disorders in Old Age, Cognitive and Behavioral Impairment
Conditions
Keywords
L-arginine, Cognitive impairment, Geriatrics, Elderly, Cognitive Function, Nitric Oxide
Brief summary
This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.
Detailed description
Cognitive decline is a common problem in the geriatric population and can significantly affect independence, quality of life, and overall health outcomes. Emerging evidence suggests that L-arginine, a semi-essential amino acid and precursor for nitric oxide synthesis, may play a role in improving cerebral blood flow and neuronal function. These mechanisms could potentially contribute to better cognitive performance in elderly individuals. This study is designed to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Participants who meet eligibility criteria will be randomized to receive either L-arginine supplementation or placebo. Cognitive function will be assessed at baseline and at defined intervals during the study period using validated neurocognitive assessment tools. Additional measures will include safety monitoring, tolerability, and secondary assessments such as quality of life indices. The primary objective is to determine whether L-arginine supplementation improves cognitive function. Secondary objectives include evaluating the anti-inflammatory, antioxidant effect and safety profile of L-arginine in older adults and assessing its potential impact on daily living and overall well-being. The results of this study may provide valuable insights into the role of L-arginine in supporting cognitive health in elderly populations and inform future clinical practice.
Interventions
DIETARY_SUPPLEMENTL-Arginine
6 grams L-arginine sachets taken orally once daily
OTHERPlacebo
Matching Placebo of L-arginine
Sponsors
German University in Cairo
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Randomized, double blinded, controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>60 years * Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)
Exclusion criteria
* Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis) * Patients with history of L-arginine intolerance or allergy * Patients with asthma * Patients who recently had an acute myocardial infarction * Patients with history of stroke within 1 yaear * Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period. * Patients who initiated or stopped antihypertensive medications during the study period. * Patients who initiated or stopped antidiabetic medications during the study period. * Patients who initiated or stopped antihyperlipidemic medications during the study period. * Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function * Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics * Refusal to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Montreal Cognitive Assessment (MOCA) | at baseline, after 2 weeks, and after 4 weeks | MOCA is a is a brief cognitive screening tool used to detect mild cognitive impairment (MCI) and early dementia. It assesses multiple cognitive domains including memory, attention, executive function, language, visuospatial skills, abstraction, calculation, and orientation. The score ranges from 0- 30. The higher the score the better the cognition. The normal range is from 26-30. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Depression, Anxiety, Stress Scales-21 (DASS-21) | at baseline, after 2 weeks, and after 4 weeks | DASS-21 is a short self-report questionnaire used to assess depression, anxiety, and stress over the past week. It consists of 21 items, with 7 items for each subscale, rated on a 4-point Likert scale. Each subscale has a raw score range of 0-21and the higher the score the worse the outcome of symptoms of depression, anxiety, or stress. |
| The World Health Organization Quality of Life (WHOQOL-BREF) | at baseline, after 2 weeks, and after 4 weeks | WHOQOL-BREF is a brief, self-administered questionnaire that assesses an individual's perceived quality of life. It consists of 26 items covering four domains: physical health, psychological health, social relationships, and environment. Score can range from 0-100 for each domain with higher scores meaning a better quality of life. |
| ADMA | at baseline and after 4 weeks | Asymmetric dimethylarginine |
| MDA | at baseline and after 4 weeks | Malondialdehyde |
| CRP | at baseline and after 4 weeks | C-reactive protein |
| Lipid Profile | at baseline and after 4 weeks | — |
| Kidney Function test | at baseline and after 4 weeks | Serum Creatinine |
| Liver Function Tests | at baseline and after 4 weeks | ALT and AST |
Countries
Egypt
Outcome results
None listed